Australia To Fund Mekinist, Xalkori But More Evidence Will Be Needed
This article was originally published in Scrip
In another example of reimbursement agencies agreeing to pay for expensive new drugs in exchange for a commitment to provide more evidence of real clinical value, two major new anticancers from Novartis and Pfizer have been recommended for funding by the Australian Pharmaceutical Benefits Scheme under managed entry schemes. The agreements include a commitment to provide more convincing data with the possibility of a price cut if the terms of the schemes are not met.
You may also be interested in...
Early interaction with the European Medicines Agency is recommended if companies are planning to incorporate digital technologies into their drug development plans.
The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.